Nasdaq lpcn.

This is a decrease of 15 owner (s) or 21.74% in the last quarter. Average portfolio weight of all funds dedicated to LPCN is 0.01%, a decrease of 21.85%. Total shares owned by institutions ...Nov 13, 2023 · SALT LAKE CITY, Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of ... By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT On May 9, 2022 Lipocine (NASDAQ:LPCN) filed its Form 10-Q and posted its earnings release for the quarter ending March 31 ...Lipocine Stock Up 3.8 %. Shares of NASDAQ LPCN opened at $2.73 on Tuesday. The firm has a market cap of $14.52 million, a PE ratio of -0.87 and a beta of …

SALT LAKE CITY, March 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019, and ...

Complete Lipocine Inc. stock information by Barron's. View real-time LPCN stock price and news, along with industry-best analysis.Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are ...

Lipocine Inc (US:LPCN) has 0 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Lipocine Inc (NASDAQ:LPCN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.SALT LAKE CITY, Nov. 1, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an abstract ...All day - Lipcone's (NASDAQ:LPCN) is on watch with a potential FDA approval on Tlando following a two-month review. The FDA issued tentative approval in December of 2020. The FDA issued tentative ...SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted tentative approval to TLANDO, its oral testosterone product for testosterone replacement therapy …

0.31%. $40.52B. LPCN | Complete Lipocine Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Nov 20, 2023 · Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are ...31 Aug 2021 ... On August 25th, 2021 Lipocine (NASDAQ:LPCN) released liver biopsy results for its Phase II LiFT study in NASH. LiFT, or Liver Fat Intervention ...SALT LAKE CITY, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) has extended ...SALT LAKE CITY, Sept. 26, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products ...Lipocine Inc (US:LPCN) has 0 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Lipocine Inc (NASDAQ:LPCN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.SALT LAKE CITY, Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of ...SALT LAKE CITY, Sept. 27, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules focused on treating CNS disorders, announced today that it will participate in the Cantor …

43053e0.BvyjoXDK4vyzPj9jPCzC6nYZaj5-AJZQTaA_XM6iJCk.Pqj27Qe6rZn4cg8Iak23njphW0oPNqA7HNJoEomXEBw1kOnSKYyXndVGCw …SALT LAKE CITY, Feb. 3, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for metabolic and endocrine disorders, today announced that Antares Pharma, Inc. issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has accepted its New …SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the full year ended ...SALT LAKE CITY, Aug. 25, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive topline 36-week results from its Phase 2 proof of concept LiFT ("Liver Fat intervention with oral Testosterone") clinical study, NCT04134091, investigating LPCN 1144 in men with biopsy-confirmed NASH.Earnings Trend: LPCN is unprofitable, but has reduced losses over the past 5 years at a rate of 15.8% per year. Accelerating Growth: Unable to compare LPCN's earnings …

2 Nov 2015 ... Lipocine Inc. (NASDAQ: LPCN). Lipocine Inc. (LPCN), a specialty pharmaceutical company yesterday announced that the FDA accepted its filing ...SALT LAKE CITY, July 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has ...

SALT LAKE CITY, May 16, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), today announced positive topline results from a pilot clinical PK bridge study of LPCN 1154 (oral brexanolone) with a ...Lipocine Inc. Common Stock (LPCN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.SALT LAKE CITY, Aug. 8, 2022 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system ("CNS") disorders, today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.SALT LAKE CITY, May 9, 2022 /PRNewswire/ -- Lipocine Inc. , a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, today announced... | June 12, 2023Lipocine Inc. 01 Nov, 2023, 08:00 ET. "Late Breaking" abstract scheduled for oral presentation on November 13. SALT LAKE CITY, Nov. 1, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a ...Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products ...SALT LAKE CITY, March 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock ...

SALT LAKE CITY, July 23, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has ...

Phase 2 Photosensitive Epilepsy Study Planned for 2H 2022. SALT LAKE CITY, July 11, 2022 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system ("CNS") disorders with high unmet medical needs, announced today that the U.S. …

SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the full year ended ...SALT LAKE CITY, July 13, 2020 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC ("Nasdaq") on July 9, 2020 indicating that Lipocine has regained compliance with …Lipocine (NASDAQ: LPCN) stock represents a biotech firm that has made major steps in the right direction. In all of 2020, the firm recorded no revenue whatsoever. Biotech involves significant ...Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are being presented at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, taking place in Boston MA. The …SALT LAKE CITY, Aug. 8, 2022 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system ("CNS") disorders, today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.View real-time LPCN stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... SALT LAKE CITY, March 3, 2021 - /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical ...By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 1Q:23 Financial and Operational Results Efforts year to date for Lipocine Inc. (NASDAQ:LPCN) were dominated by the pharmacokinetic (PK) study for LPCN 1154, which is in development for postpartum depression (PPD). The underlying drug in LPCN 1154 is brexanolone, which is approved in an intravenous (IV) formulation for PPD.Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers …By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Second Quarter 2022 Financial and Operational Results On August 8, 2022 Lipocine (NASDAQ:LPCN) filed its second quarter ...

SALT LAKE CITY, Feb. 3, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for metabolic and endocrine disorders, today announced that Antares Pharma, Inc. issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has accepted its New …SALT LAKE CITY, June 23, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data will be presented at The International Liver Congress™ 2021, the annual meeting of the European Association for the Study of the Liver ("EASL"), …SALT LAKE CITY, Aug. 8, 2022 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system ("CNS") disorders, today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.May 20, 2022 · By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT NASH Open Label Extension Study Results On May 12, 2022 Lipocine (NASDAQ:LPCN) announced results from its NASH Open Label Extension (OLE) study. Safety was confirmed with no observed safety signals over the 72-week duration of exposure and liver injury markers were either maintained or reduced with the use of LPCN 1144. The Instagram:https://instagram. iwm etf priceamazon stock to buyhow to use forex to make moneydoes webull have crypto SALT LAKE CITY, May 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results ... stocks upgrade downgradeally financial news The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange. best dental insurance ohio SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an ...Oct 26, 2023 · 26 Oct, 2023, 08:00 ET. Lipocine and FDA agreed on the acceptance criteria for the pivotal study which enables advancement of LPCN 1154 for postpartum depression (PPD) Company on track to initiate ... Jun 30, 2022 · By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Second Quarter 2022 Financial and Operational Results On August 8, 2022 Lipocine (NASDAQ:LPCN) filed its second quarter 2022 Form 10-Q and posted its earnings release for the quarter ending June 30, 2022. Highlights for the second quarter 2022 and to-date include: New board of director appointments – April 2022 LPCN 1144